US Earnings Financial Results SEC Filings — March 12, 2026

12-03-2026

CareCloud, Inc.'s 10-K filing outlines extensive risk factors, including dependencies on offshore operations in Pakistan, Azad Jammu and Kashmir, and Sri Lanka; challenges integrating acquisitions like MAP App, Medsphere Systems Corporation, and RevNu Medical Management; cybersecurity threats; and competition in adopting AI. Key personnel risks involve retaining Mahmud Haq (Executive Chairman), Stephen Snyder (CEO), and A. Hadi Chaudhry (Chief Strategy Officer), while dividends on Series A and B Preferred Stock—suspended in December 2023 and resumed in February 2025—remain in arrears with double payments planned from February 2026, subject to lender covenants. Additional concerns include potential goodwill impairments, preferred stock conversions diluting common shares (majority in March 2025), and Mahmud Haq's 12% ownership control as of December 31, 2025, with no offsetting positive performance metrics provided.

• ·Dividends on Preferred Stock suspended in December 2023; resumed February 2025 with one month of arrearage paid monthly; double dividends on Series B starting February 2026.
• ·Majority of Series A Preferred Stock converted to common stock in March 2025, increasing outstanding shares and granting full voting rights.

12-03-2026

Acurx Pharmaceuticals, Inc. (ACXP) filed its 10-K Annual Report on March 12, 2026, detailing significant risk factors including ongoing net losses since inception with no anticipated profitability in the foreseeable future. Key risks encompass potential failure to obtain regulatory approval for product candidate ibezapolstat, challenges in establishing sales/marketing capabilities, reimbursement limitations from third-party payers, high commercialization costs, supply chain disruptions, and international uncertainties such as Brexit. While the company believes ibezapolstat can be priced competitively due to low manufacturing costs compared to generics like vancomycin and metronidazole for CDI treatment, commercialization remains uncertain.

12-03-2026

Horizon Kinetics Holding Corp's 2025 revenue rose 31% YoY to $72.8M from $55.8M, driven by 31% growth in management and advisory fees to $72.4M, while operating expenses fell 13% to $61.8M, swinging operating income to a $11.1M profit from a $15.1M loss. However, net income attributable to HKHC plummeted 95% to $5.1M from $92.5M, primarily due to a sharp drop in net investment income of consolidated products to -$17.8M from $840.7M and unrealized investment losses; operating cash flow turned negative at -$43.1M from $11.8M positive. Total assets edged down 1.6% to $2.0B, though cash equivalents more than doubled to $36.9M.

• ·EPS attributable to HKHC: $0.27 (2025) vs $5.07 (2024)
• ·Dividends paid: $6.3M (2025) vs $1.0M (2024)
• ·Deferred tax liability declined to $66.3M from $95.7M

12-03-2026

Grayscale Zcash Trust (ZCSH), which holds approximately 2.4% of ZEC in circulation as of December 31, 2025, reported shares outstanding of 4,829,300 as of March 6, 2026, with non-affiliate market value of $14.4M as of June 30, 2025. While the Trust plans to convert to an ETF structure with NYSE Arca listing and redemption program pending SEC approval, shares have historically traded at substantial premiums (max 240%, avg 53%) and discounts (max 55%, avg 20%, with 583 discount days), ending the year at a 24% discount to NAV per Share. Each Share represented 0.0815 ZEC as of year-end.

• ·Trust formed on October 23, 2017; name changed January 11, 2019.
• ·Sponsor changes: Reorganization January 1, 2025; GSO withdrew January 3, 2025; GSIS sole Sponsor effective May 3, 2025.
• ·S-3 registration filed November 2025 for potential public offering and NYSE Arca listing under ZCSH.

12-03-2026

Sonida Senior Living, Inc. reported resident revenue growth of 23.9% YoY to $332M for FY 2025, driven by expansion to 80 communities (+3.9%) and higher RevPAR (+7.9%), with community NOI up 21.6% to $83M and Adjusted EBITDA rising 24.3% to $54M. However, net loss widened dramatically to $72.5M from $3.3M due to $12.5M long-lived asset impairment, higher depreciation (+28.9%), transaction costs ($16.2M), and no repeat of prior year's $48.5M debt extinguishment gain, while overall occupancy dipped 0.7% to 84.7%. Same-store revenue grew modestly 6.1% with NOI up 8.0%, but average units were flat at +0.2%.

• ·Management fee revenue increased 31.1% YoY to $4.4M.
• ·Transaction, transition and restructuring costs rose to $16.2M from $5.9M.
• ·Interest expense up 4.4% to $38.6M.
• ·Net cash used in investing activities improved to $70.7M outflow from $209M.
• ·Investment Agreements dated November 4, 2025 with Conversant entities and Silk Partners, LP.
• ·Amended and Restated Investor Rights Agreement dated March 10, 2026.

12-03-2026

Orrstown Financial Services reported average total assets of $5.43B in 2025, up 25.7% YoY from $4.32B, fueled by 25.2% loan growth to $3.95B average balance and net interest income expansion of 28.7% to $199.8M with NIM improving to 4.04%. Noninterest income surged 39.7% YoY to $52.3M, driven by trust/brokerage and swap fees, while noninterest expenses remained nearly flat at $149.4M (up 0.7%) due to sharply lower merger-related costs ($2.6M vs $22.7M). However, mortgage banking income declined 1.6% YoY and investment securities gains fell 33.3%.

• ·Accretion on purchase accounting marks: $21.5M in 2025 (vs $15.2M in 2024)
• ·Merger-related expenses: $2.6M in 2025 (down from $22.7M in 2024)
• ·Investment securities portfolio book value $972.1M with average maturity 23.3 years
• ·Salaries and employee benefits up 11.2% YoY to $85.2M

12-03-2026

Grayscale XRP Trust ETF's net assets surged to $223.4M at December 31, 2025 from $10.5M at December 31, 2024, fueled by massive capital inflows with shares outstanding rising from 250,800 to 6,300,100. However, NAV per share fell 15% to $35.45 from $41.67, driven by a net operational loss of $37.9M in 2025 versus a $7.2M gain in the prior partial-year period, primarily from $37.8M unrealized depreciation on XRP investments. XRP holdings expanded to 122.2 million units at fair value of $223.4M (cost basis $253.9M).

• ·Trust commenced operations on September 5, 2024
• ·No shares redeemed in either period
• ·No investment income reported in either period
• ·Sponsor’s Fee Waiver of $67K in 2025
• ·Net cash used in operating activities: $248.1M; provided by financing: $248.1M (2025)
• ·Q4 2025 showed sharp unrealized depreciation of $41.5M, contributing to overall ops loss

12-03-2026

Adicet Bio, Inc. reported a net loss of $116.8M for the year ended December 31, 2025, nearly flat at a 0% change from $117.1M in 2024, with total operating expenses declining 4% to $122.1M due to a 19% drop in G&A to $23.0M, while R&D expenses remained flat at 0% or $99.1M. However, interest income fell 46% to $5.8M, cash used in operating activities increased to $95.2M from $92.4M, cash and equivalents dropped to $38.9M from $56.5M, and total assets decreased to $192.4M from $220.2M.

• ·Common shares outstanding increased to 9.6M from 5.2M, driven by public offering of 4.4M shares net $74.8M.
• ·Stock-based compensation expense declined to $14.3M from $22.2M.
• ·Net loss per share improved to ($16.95) from ($21.33) due to higher share count.
• ·Short-term investments stable at ~$119.7M vs $119.8M.

12-03-2026

TEAM Inc's FY2025 total revenues grew 5.2% YoY to $896.5M, with IHT segment up 7.5% to $458.9M while MS increased modestly 2.8% to $437.6M. Operating income rose 38.8% to $14.1M, and Adjusted EBITDA improved to $60.7M from $54.3M; however, net loss widened 28.6% to $49.2M due to a $13.1M debt extinguishment loss and higher other expenses, with MS operating income declining 3.2% and free cash flow turning negative at $(20.6M) versus $13.3M prior year.

• ·Cash and cash equivalents declined to $18.1M from $35.5M YoY.
• ·Total assets decreased to $485.5M from $528.4M.
• ·Long-term debt reduced to $293.3M from $318.6M.
• ·Shareholders’ equity turned to deficit of $(24.5M) from $1.7M.
• ·Operating cash flow swung to $(11.3M) from $22.8M.

12-03-2026

Net assets increased 56% YoY to $160.4M at December 31, 2025 from $102.6M, driven by $107.1M in capital share issuances and shares outstanding more than doubling to 17.6M; however, operations showed a $49.3M net decrease due to $49.5M unrealized depreciation on SOL investments, contrasting with a $32.3M gain in 2024. NAV per share declined 37% to $9.09 from $14.33 amid SOL price weakness, while new staking rewards provided $1.6M income but expenses rose to $2.0M. Compared to 2023's $25.2M net assets, growth remains strong over two years but operational performance deteriorated sharply.

• ·No share redemptions occurred in 2023-2025.
• ·Cash balance remained at $0 throughout, with financing fully offsetting operating cash use via share issuances.
• ·SOL cost basis Dec 31, 2025: $175.0M vs fair value $160.4M (unrealized loss); Dec 31, 2024: $67.8M cost vs $102.6M fair value (gain).

12-03-2026

Elicio Therapeutics reported a reduced net loss of $39.6M for the year ended December 31, 2025, improving 23.8% YoY from $51.9M, primarily due to operating expenses declining 16.2% to $37.7M, with R&D expenses dropping sharply 26.0% to $24.9M. However, G&A expenses increased 13.1% to $12.8M, cash used in operating activities remained nearly flat at $37.0M, total assets decreased to $25.9M from $28.2M, and net cash position slightly declined by $225K. Stockholders' equity improved to a positive $1.6M from a $11.3M deficit, supported by financing activities including stock issuances.

• ·Net cash provided by financing activities: $36.7M in 2025 vs $42.3M in 2024.
• ·Long-term debt, net: $9.4M at Dec 31 2025 vs $20.0M at Dec 31 2024.
• ·Warrant liabilities: $2.6M at Dec 31 2025 vs $2.8M at Dec 31 2024.
• ·Cash, cash equivalents and restricted cash: $19.3M at Dec 31 2025 vs $19.5M at Dec 31 2024.
• ·Weighted average common shares outstanding: 15,312,751 in 2025 vs 12,202,996 in 2024.
• ·Net loss per common share: $(2.58) in 2025 vs $(4.25) in 2024.

12-03-2026

Grayscale Ethereum Classic Trust (ETCG) filed its 10-K for the fiscal year ended December 31, 2025, disclosing it holds approximately 7% of ETC in circulation, with each Share representing 0.7850 ETC and 13,993,800 Shares outstanding as of March 6, 2026. Shares have historically traded at substantial premiums (max 458%, avg 98%) and discounts (max 77%, avg 45%) to NAV per Share since May 10, 2018, with a 28% discount as of December 31, 2025, due to lack of redemption program and volatility. The filing emphasizes risks including ETC price volatility, regulatory uncertainties, and potential Trust dissolution.

• ·Trust formed April 18, 2017; name changed January 11, 2019.
• ·Reorganization January 1, 2025; GSO withdrew January 3, 2025; GSIS sole Sponsor effective May 3, 2025.
• ·No ongoing redemption program; creations in Baskets of 100 Shares.
• ·Shares trade on OTCQX; private placement Shares subject to Rule 144 six-month holding period.

12-03-2026

Grayscale Dogecoin Trust ETF (GDOG), sponsored by Grayscale Investments Sponsors, LLC, filed its 10-K for FY ended December 31, 2025, detailing its operations as a passive vehicle holding Dogecoin (DOGE) with 624,700 shares outstanding as of March 6, 2026, and each share representing approximately 117.5835 DOGE. The Trust uplisted on NYSE Arca on November 24, 2025, after which shares traded with an average premium of 0.08% but also an average discount of 0.24% to NAV per share through year-end. Extensive risk factors highlight DOGE price volatility, regulatory uncertainties, and potential for shares to trade at premiums or discounts to NAV.

• ·Trust formed January 27, 2021; operations commenced January 30, 2025.
• ·Name changed to ETF on November 20, 2025; uplisted on NYSE Arca November 24, 2025.
• ·Sponsor changes: Reorganization January 1, 2025; GSO withdrew January 3, 2025; GSIS sole sponsor effective May 3, 2025.
• ·SEC approved NYSE Arca generic listing standards September 17, 2025.

12-03-2026

CompoSecure, Inc. reported net sales of $59.8M for the year ended December 31, 2025, an 86% YoY decline from $420.6M in 2024, driven by sharp drops in both domestic sales (-84%) and international sales (-93%), resulting in a gross margin contraction to 48% from 52% and a net loss widening to $136.0M from $83.2M. However, Adjusted EBITDA improved 13% to $171.8M from $151.4M, and Adjusted net income rose to $120.8M from $98.2M, reflecting non-GAAP adjustments for mark-to-market gains and transaction costs. In the prior year, 2024 sales had grown 8% YoY from 2023, but operating margins fell to 26% from 30%.

• ·Adjusted net income per share - basic: $1.09 (2025) vs $1.17 (2024)
• ·Adjusted net income per share - diluted: $1.00 (2025) vs $0.95 (2024)
• ·Mark to market adjustments, net: $208.1M (2025) vs $171.8M (2024)

12-03-2026

Bitwise Ethereum ETF (ETHW), a Delaware statutory trust formed on February 16, 2024, filed its 10-K annual report for the fiscal year ended December 31, 2025, disclosing 15,280,000 shares outstanding as of March 3, 2026, and an aggregate market value of non-affiliate common equity of $269.3M as of the end of its second fiscal quarter. The Trust, which commenced operations on July 22, 2024, and trading on NYSE Arca on July 23, 2024, holds primarily ether with NAV referenced to the CME CF Ether-Dollar Reference Rate (New York variant) at $2,964.79 on December 31, 2025; no period-over-period financial performance data or declines were detailed in the provided sections.

• ·Trust formed on February 16, 2024; Sponsor Agreement dated July 9, 2024; Trust Agreement dated May 28, 2024.
• ·Commission file number: 001-42159; I.R.S. Employer Identification No.: 99-6361348.
• ·Baskets created/redeemed in blocks of 10,000 Shares based on Basket Amount of ether.
• ·Ether Trading Counterparties as of December 31, 2025: B2C2 USA Inc., Coinbase, Inc., Cumberland DRW LLC, FalconX, Flow Traders B.V., JSCT, LLC, Nonco LLC, Virtu Financial Singapore Pte. Ltd., Wintermute Trading Ltd.
• ·Constituent Platforms for Pricing Index as of December 31, 2025: Bitstamp, Coinbase, Gemini, itBit, LMAX Digital, Kraken, Crypto.com, Bullish Exchange.

12-03-2026

INTEST CORP reported total revenue of $113.8M for the year ended December 31, 2025, down 12.9% YoY from $130.7M in 2024, primarily due to declines in Process Technologies (-25.3% to $28.3M) and Electronic Test (-12.0% to $56.2M), while Environmental Technologies showed flat growth of 1.4% to $29.3M. Sub-markets were mixed, with strong gains in Life Sciences (+67.5% to $9.0M) and Industrial (+30.0% to $17.4M), but sharp drops in Auto/EV (-30.9% to $22.7M) and Semi (-26.2% to $36.0M). Gross profit fell 11.7% to $48.9M, though gross margin improved to 43.0% from 42.4%.

• ·Selling expense declined 3.4% to $16.8M (14.7% of revenue), Engineering and product development expense rose 10.4% to $9.4M (8.3% of revenue), General and administrative expense fell 5.7% to $22.2M (19.5% of revenue), Amortization of acquired intangible assets increased 31.5% to $3.3M (2.9% of revenue), Restructuring costs of $0.9M (0.7% of revenue) in 2025.
• ·Defense/Aerospace revenue down 6.9% to $14.3M, Safety/Security down 1.8% to $2.9M (flat), Other down 4.4% to $11.5M.

12-03-2026

Net assets of Grayscale Chainlink Trust ETF grew 229% YoY to $73,816 at December 31, 2025 from $22,437, driven by $70,805 in capital share transactions that increased shares outstanding 449% to 6,792,010. However, principal market NAV per share declined 40% to $10.87 due to a $18,889 unrealized depreciation on LINK investments, resulting in a net operational loss of $19,426 versus a $4,222 gain in 2024. Expenses rose 67% YoY to $509 amid sponsor fees, with no investment income.

• ·No investment income reported in 2025, 2024, or 2023.
• ·LINK holdings quantity increased to 6,029,727 at Dec 31, 2025 from 1,124,122 at Dec 31, 2024.
• ·No shares redeemed in 2025, 2024, or 2023.
• ·Cash remains at $0 end of 2025; all activities in-kind.
• ·Sponsor’s Fee waiver of $20 in 2025.

12-03-2026

Bath & Body Works reported FY2025 net sales of $7,291M, down 0.2% YoY to $7,307M, driven by a 0.9% increase in stores sales to $5,582M but a 5.4% decline in direct sales to $1,395M, while international sales grew 4.9% to $314M. Reported operating income fell 11% to $1,126M from $1,266M, and net income decreased to $649M from $798M with diluted EPS at $3.11 versus $3.61. However, net cash from operating activities surged 24% to $1,102M, boosting free cash flow 31% to $865M and ending cash balances to $953M.

• ·Adjusted Operating Income declined to $1,156M from $1,266M YoY.
• ·Debt Leverage Ratio increased to 2.7x from 2.5x.
• ·Total ordinary dividends remained flat at $0.80 per share, with total paid $167M vs $177M.
• ·Total Selling Square Feet increased 2% to 5,493 thousand.

12-03-2026

AMES National Corp's 10-K for 2025 reports a $656M investment securities portfolio with a weighted average yield of 2.26%, while fair value of states and political subdivisions obligations declined 3.4% YoY to $237M. Average total deposits grew modestly 0.6% YoY to $1.83B, but noninterest-bearing deposits fell 4.8% to $325M amid rate compression across categories; borrowings decreased sharply 39.5% to $60M. Asset quality was stable with nonperforming assets flat at $15.7M (1%) YoY and net charge-offs minimal at $357k or 0.03% of average loans.

• ·General obligation bonds fair value $135M (2025) vs $139M (2024), down 2.8% YoY
• ·Revenue bonds fair value $102M (2025) vs $107M (2024), down 4.4% YoY
• ·Average time certificates $333M (2025, up 8.4% YoY) at 3.78% rate (down from 4.12%)
• ·Nonaccrual loans $15.1M (2025, up 2.4% YoY from $14.8M)

12-03-2026

Eastman Kodak Co reported FY2025 revenues of $1,069M, up 2.5% YoY from $1,043M, with strong growth in Advanced Materials and Chemicals (+17% to $316M) and Brand (+15% to $23M), while Print revenues declined 3% to $715M. Gross profit rose 14% to $232M (22% margin) from $203M (19%), but the company posted a net loss of $128M versus a $102M profit in 2024, driven by $171M other charges and higher restructuring costs. Cash and equivalents increased to $442M from $301M, supported by robust operating cash flow of $480M versus -$7M.

• ·Print Operational EBITDA improved to $3M (0% of revenues) from -$8M (-1%)
• ·Advanced Materials and Chemicals Operational EBITDA margin expanded to 12% from 6%
• ·Brand Operational EBITDA margin stable at 87% vs 85%
• ·Cash increased $141M net, with investing cash outflow reduced to $29M from $39M

12-03-2026

For the three months ended January 31, 2026, Mission Produce, Inc. reported net sales of $278.6M, down 17% YoY from $334.2M, while gross profit remained essentially flat at $31.6M versus $31.5M. Operating income declined 73% to $2.5M from $9.3M due to SG&A expenses rising 31% to $29.1M, leading to a net loss of $0.1M compared to net income of $6.2M in the prior year. Balance sheet total assets grew 1.5% QoQ to $997.7M with inventory up 23% to $99.3M, but cash and equivalents fell 31% to $44.8M from $64.8M.

• ·Net cash used in operating activities increased to $3.0M from $1.2M YoY.
• ·Net cash used in investing activities improved to $11.8M from $14.9M YoY.
• ·Shares outstanding increased to 70,839,275 as of Jan 31, 2026 from 70,569,517 as of Oct 31, 2025.
• ·Stock-based compensation expense was $1.4M in the current period.

12-03-2026

LINKBANCORP reported net income of $33.5M for 2025, up 28% YoY from $26.2M, driven by net interest income growth of 4% to $104.3M, higher noninterest income from $11.1M branch sale gain, and loan growth of 13% to $2.53B net. However, provision for credit losses surged to $8.2M from $0.3M, NIM declined to 3.81% from 3.88%, loan yields fell to 6.27% from 6.38%, and noninterest-bearing deposits dropped 8% to $604M.

• ·Securities AFS increased to $262.6M from $145.6M.
• ·Interest-bearing deposits grew to $1.95B from $1.70B.
• ·Shareholders' equity rose to $306.4M from $280.2M.
• ·EPS basic $0.90 vs $0.71.

12-03-2026

Grayscale Bittensor Trust (GTAO), a Delaware Statutory Trust formed on April 30, 2024, issued its 10-K for FY ended December 31, 2025, reporting it holds approximately 0.3% of TAO in circulation with each Share representing ~0.0192 TAO; 1,907,800 Shares were outstanding as of March 6, 2026. Shares traded on OTCQX at substantial premiums to NAV per Share, with a maximum of 124% and average 65% premium from December 12-31, 2025, and 124% as of December 31, 2025, due to lack of redemption program, Rule 144 holding periods, and other factors preventing arbitrage. The Trust filed an S-1 in December 2025 for potential NYSE Arca listing as an ETF with redemption program, though not yet effective.

• ·Trust formed April 30, 2024; Sponsor changed to GSIS effective May 3, 2025 post-Reorganization.
• ·Index changed from Coin Metrics Real-Time Rate to CoinDesk Bittensor Benchmark Rate effective March 6, 2026.
• ·Shares issued in Baskets of 100 to Authorized Participants; currently no redemption program.
• ·Private placements only; OTCQX quoted but not listed on national exchange.

12-03-2026

Inflection Point Acquisition Corp. IV (BACQU) filed its 10-K annual report on March 12, 2026, disclosing risks from potential debt obligations, including substantial cash flow allocation to principal and interest payments that could limit funds for dividends on Class A Shares, expenses, capital expenditures, acquisitions, and strategy execution. The filing highlights limitations on additional borrowing compared to less-leveraged competitors and potential control changes from issuing substantial Class A Ordinary Shares. It notes potential repayments of up to $750,000 in working capital loans from Inflection Point Fund I LP and up to $2,500,000 in Sponsor-related loans convertible into private placement units at $10.00 per unit, with consolidated financial statements provided from pages F-2 to F-24.

• ·Consolidated financial statements include Balance Sheets (F-3), Statements of Operations (F-4), Changes in Shareholders’ Deficit (F-5), and Cash Flows (F-6), with Notes from F-7 to F-24.

12-03-2026

National Beverage Corp reported net sales of $264.6M for the three fiscal months ended January 31, 2026, down 0.9% YoY from $267.1M, while nine-month sales declined 0.5% YoY to $883.4M from $887.7M. However, gross profit rose 0.7% to $99.6M (three months) and 1.1% to $334.3M (nine months), driving operating income up 1.1% to $51.1M and $180.0M respectively, and net income up 3.9% to $41.2M (three months) and 0.9% to $143.3M (nine months). Cash and equivalents surged 62% to $314M, boosting total assets 18% to $792M and shareholders' equity 33% to $591M, though operating cash flow dipped 7% YoY to $136M.

• ·Trade receivables decreased to $97M from $104M year-over-year balance sheet comparison.
• ·Inventories increased to $96M from $85M as of May 3, 2025.
• ·Total liabilities declined 12% to $201M from $229M.
• ·Capital expenditures were $15M for nine months, down from $21M prior year.
• ·No dividends paid on common stock in nine months ended Jan 31, 2026 (prior year: $304M).

12-03-2026

WM Technology, Inc. reported FY2025 revenues of $174.7M, down 5% YoY from $184.5M, with net income declining sharply to $3.3M from $12.2M and EBITDA falling to $15.0M from $25.1M. Adjusted EBITDA decreased slightly to $39.8M from $42.9M, pressured by a 9% rise in G&A expenses to $76.9M and new $7.8M asset impairment charges, though product development costs dropped 23% to $28.1M and average monthly paying clients grew modestly to 5,190 from 5,077. Cash and equivalents improved to $62.4M from $52.0M, but operating cash flow fell to $26.2M from $36.7M.

• ·Working capital increased to $48.7M as of Dec 31, 2025 from $39.1M.
• ·Accounts receivable, net rose to $14.6M from $10.1M.
• ·Total costs and expenses up 2% YoY to $173.9M, reaching 99.6% of revenue vs 92.0% prior year.
• ·Net income attributable to WM Technology, Inc. was $2.0M (1.1% of revenue) vs $7.6M (4.1%) in 2024.

12-03-2026

WEIS MARKETS INC reported FY2025 net sales of $4.94B, up 3.5% YoY from $4.77B in FY2024, with comparable store sales excluding fuel rising 2.1% and pharmacy services sales mix increasing to 13.6% from 12.5%. However, income from operations fell 10.1% to $113.7M with operating margin contracting to 2.3% from 2.6%, while net income declined 11.6% to $93.7M and diluted EPS dropped 7.4% to $3.65. Gross profit margin remained flat at 25.1%, and center store sales mix decreased to 52.6% from 53.7%.

• ·O, G & A expenses increased 5.0% YoY to $1,126.2M in FY2025, or 22.8% of net sales (up from 22.5%).
• ·Employee expense increased $19.7M in FY2025 vs FY2024 (0.0% of sales).
• ·Investment income and interest expense declined 33.1% to $15.0M in FY2025.
• ·Weis Markets Charitable Foundation established in November 2025.

12-03-2026

Pioneer Bancorp, Inc./MD reported strong balance sheet growth with total assets increasing 8.7% YoY to $2.15B, net loans up 14.8% to $1.65B, and deposits rising 9.6% to $1.74B at December 31, 2025. Net income for the full year 2025 reached $20.3M with EPS of $0.83, compared to $15.3M and $0.61 EPS for FY 2024 ended June 30. However, non-performing assets more than doubled to $11.3M from $5.2M, pushing non-performing loans to 0.67% of total loans (up from 0.36%) and non-performing assets to 0.52% of total assets (up from 0.27%).

• ·Provision for credit losses was $3.7M for year ended Dec 31, 2025, up from $220K for six months ended Dec 31, 2024.
• ·Non-accrual residential mortgages increased to $3.9M from $4.1M (slight decline), but commercial real estate non-accrual rose to $6.1M from $0.
• ·Shareholders’ equity grew to $324M from $305M YoY.

12-03-2026

Funko, Inc. reported net sales of $908M for the year ended December 31, 2025, down 13.5% from $1.05B in 2024, with cost of sales declining 9.5% but SG&A expenses down only 5.9%. The company swung to an operating loss of $46M from a $13M profit, resulting in net loss widening to $68M (357.7% worse) from $15M, and Adjusted EBITDA falling to $27M from $95M. Cash from operations turned negative at $5M from $124M provided.

• ·Largest facility: 862,000 sq ft Warehouse/Distribution in Buckeye, AZ (lease expires Oct 31, 2032)
• ·Net cash change: +$7.5M in 2025 vs -$1.8M in 2024
• ·2023 net sales: $1.10B, net loss attributable to Funko: $154M
• ·Loss per diluted share: $(1.24) in 2025 vs $(0.28) in 2024

12-03-2026

Transact Technologies Inc's annual 10-K for year ended December 31, 2025, shows overall sales growth with segments increasing 16.4% to $25.0M (48.6% of total), 13.7% to $11.3M (21.9%), and a casino/gaming subtotal up 20% to $19.3M driven by 33% hardware growth to $7.1M, though software recurring grew only 13.5% to $12.2M. However, one segment declined 4.0% to $6.7M (13.0% of total) and another grew modestly 2.9% to $8.4M (16.4%). Facility leases in Ithaca NY, Doncaster UK, and Macau China expire in 2026.

• ·Facilities: Hamden CT (3,630 sq ft, leased to Dec 31, 2029); Ithaca NY (73,900 sq ft, to May 31, 2026); Las Vegas NV (9,400 sq ft, to Jun 30, 2031); Doncaster UK (6,000 sq ft, to Aug 24, 2026); Macau China (180 sq ft, to Apr 30, 2026).
• ·Risks include cargo delays from port security, labor disputes like dock strikes, and reliance on limited shipping/air carriers.

12-03-2026

Unknown Company's FY2025 net income declined 55% YoY to $965M from $2.13B in FY2024, driven by a $452M loss in fair value changes for reinsurance-related embedded derivatives and a 44% drop in net annuity product features to $1.175B. However, Group Protection operating income rose 30% YoY to $439M on explosive 336% revenue growth to $4.75B, and Life Insurance operating income increased 39% to $200M. Annuities operating income fell 7% to $867M while Retirement Plan Services remained flat at $150M.

• ·Filing Date: March 12, 2026
• ·Changes in fair value of reinsurance-related embedded derivatives: -$452M pre-tax in FY2025 (vs +$203M in FY2024)
• ·Net annuity product features pre-tax: $1.175B in FY2025 (down from $2.085B in FY2024)
• ·GLB rider fees ceded to LNBAR pre-tax: -$941M in FY2025
• ·Investment commitments: $4.65B total

12-03-2026

AMREP Corporation reported strong Q3 revenue growth of 94% YoY to $14.6M, driven by land sales (+184% to $8.3M) and home sales (+33% to $5.4M), leading to net income surging 339% to $3.1M; however, for the nine months ended January 31, 2026, total revenues grew modestly 8.6% YoY to $41.8M with land sales declining 8% to $16.6M despite home sales up 23%. Balance sheet strengthened with total assets up 8% to $144M, cash at $50M (up 27%), and shareholders' equity at $139M, while real estate inventory remained flat at $66.8M.

• ·Operating cash flow for nine months increased 47% YoY to $10.7M.
• ·Homebuilding model and completed inventory decreased to $8.7M from $13.1M as of Apr 30, 2025.
• ·General and administrative expenses rose 26% YoY to $6.7M for nine months.
• ·Weighted average shares outstanding - basic: 5,334k for nine months 2026 vs 5,316k in 2025.

12-03-2026

American Public Education, Inc. (APEI) reported FY2025 revenue of $648.9M, up 3.9% YoY from $624.6M in FY2024, with strong growth in RU segment (+13.9% to $246.2M) and HCN (+11.4% to $75.0M), but APUS grew only 0.9% to $319.8M (flat) and Corporate/Other declined 67.4% to $7.8M. Net income improved to $31.6M (4.8% margin) from $16.1M (2.6% margin), with operating income up 45.0% to $47.9M; however, total assets fell to $521.4M from $570.1M amid preferred stock redemption and asset sales. Diluted EPS rose to $1.36 from $0.55, while cash and equivalents increased to $176.5M.

• ·Operating cash flow increased to $62.0M in FY2025 from $48.9M in FY2024.
• ·Net cash used in financing activities was $49.2M in FY2025, primarily due to $43.2M preferred stock redemption.
• ·Accumulated deficit improved to $16.5M as of Dec 31, 2025 from $41.8M as of Dec 31, 2024.
• ·Long-term debt increased slightly to $94.7M as of Dec 31, 2025 from $93.4M.
• ·Loss on sale of subsidiary: $3.9M in FY2025.

12-03-2026

Plus Therapeutics, Inc. reported a widened net loss of $22.4M for the year ended December 31, 2025, up 73% YoY from $13.0M in 2024, primarily due to a $2.6M negative change in fair value of derivative instruments and 22% higher G&A expenses at $12.1M, despite a 21% reduction in R&D expenses to $8.4M and flat total operating expenses. Cash, cash equivalents, and restricted cash surged to $8.8M from $0.08M, bolstered by $30.3M in financing activities including stock issuances, though operating cash use intensified to $20.8M from $10.6M. Total assets expanded 146% to $16.3M with working capital flipping to a $2.9M surplus from a $10.3M deficit, amid massive common stock dilution to 138.9M shares outstanding.

• ·Net loss per share improved to $(0.29) basic from $(1.95) due to dilution.
• ·Common stock authorized increased to 2B shares in 2025 from 100M in 2024.
• ·Line of credit balance reduced to $0.8M from $3.3M.
• ·Accounts payable and accrued expenses decreased to $5.9M from $11.3M.
• ·Current liabilities declined 21% to $12.3M from $15.6M.

12-03-2026

SYNLOGIC, INC. reported a significantly reduced net loss of $1.0M for the year ended December 31, 2025, compared to $23.4M in 2024, driven by a 90% decrease in total operating expenses to $4.0M, including R&D expenses dropping 100% to $43K and restructuring charges falling 98% to $476K. However, revenue declined 100% to $0 from $8K, G&A expenses decreased 47% but remained at $3.5M, and cash and equivalents fell to $14.7M from $18.9M with net cash used in operations at $4.4M.

• ·Purchase warrant liability: $2.6M as of Dec 31, 2025 (down from $4.9M in 2024)
• ·Total stockholders' equity: $11.9M as of Dec 31, 2025 (down from $12.8M in 2024)
• ·Net loss per share basic and diluted: $(0.08) in 2025 vs $(1.92) in 2024
• ·Filing date: March 12, 2026

12-03-2026

Acacia Research Corporation reported total revenues of $285.2M for 2025, surging 133% YoY from $122.3M, fueled by paid-up license revenue growth of 346% to $76.9M and industrial operations revenues up 30% to $63.8M, leading to a net income turnaround to $21.7M from a $36.1M loss in 2024. Production volumes increased 24% YoY to 2.1M Boe with gains across oil (+24%), natural gas (+25%), and NGLs (+23%). However, recurring license revenues declined 34% to $1.5M, oil prices dropped 13% to $63.02/Bbl, NGL prices fell 6%, and total costs/expenses rose 80% to $278.8M.

• ·New license agreements executed decreased to 6 from 9 (-33%).
• ·Inventor royalties increased 895% to $17.2M.
• ·Parent general and administrative expenses declined 19% to $24.7M.
• ·Cost of revenues - industrial operations slightly down 3% to $14.5M.

12-03-2026

GRAIL, Inc. reported total revenue of $147.2M for the year ended December 31, 2025, up 17% YoY from $125.6M, driven by strong 28% growth in screening revenue to $138.6M; however, development services revenue declined sharply 49% to $8.6M. Operating expenses fell 69% to $709.3M, with significant reductions in R&D (-39%), sales and marketing (-24%), G&A (-26%), and goodwill impairment (-98% to $28M from $1.42B), narrowing the net loss 80% to $408.4M; nonetheless, cost of screening revenue rose 16% to $73.3M and remained at 53% of screening revenue (improved from 58%).

• ·Interest income increased 7% to $28.7M from $26.7M.
• ·Cost of screening revenue increased 16% to $73.3M from $63.3M.
• ·Compensation expenses within R&D declined 37% to $102.6M.

12-03-2026

Omega Flex, Inc. (OFLX) reported FY2025 net sales of $98.3M, down 3.3% YoY from $101.7M, with gross profit declining 5.3% to $59.0M at a 60.0% margin (vs 61.2% prior). Operating profit fell sharply 21.6% to $16.9M, resulting in net income attributable to OFLX of $14.8M (-17.7% YoY) and diluted EPS of $1.47 (vs $1.78), though cash dividends per share increased slightly to $1.36 from $1.35. Balance sheet stable with total assets at $105.0M (down 0.9%), cash up 3.0% to $53.2M, shareholders' equity up 1.0% to $84.0M, and operating cash flow of $17.2M (-17.6% YoY).

• ·Capital expenditures decreased to $1.8M from $2.0M YoY.
• ·Accounts receivable down to $13.7M from $14.4M; inventories down to $13.4M from $14.6M.
• ·Current liabilities decreased to $16.0M from $17.4M.
• ·Noncontrolling interest shifted to loss of $178K from gain of $67K.

12-03-2026

GoPro's FY 2025 total revenue declined 19% YoY to $652M from $801M, driven by a 25% drop in camera units shipped to 1.8M despite an 8% rise in average selling price; hardware revenue fell 21% while subscriptions remained nearly flat at $106M. Operating expenses decreased 26% to $303M, leading to a significantly narrowed net loss of $93M (78% improvement YoY), with Q4 revenue flat at $202M and positive cash from operations of $16M. Regionally, Americas grew 1% to $383M, but EMEA declined 26% and APAC plunged 53%.

• ·Gross margin declined 20 bps YoY to 33.6% in FY 2025.
• ·Goodwill impairment charge of $19M in FY 2025.
• ·Adjusted EBITDA improved to -$29M in FY 2025 from -$72M.
• ·Retail channel revenue down 20% to $482M (74% of total), GoPro.com down 15% to $170M (26% of total).
• ·R&D expenses down 32% to $127M, sales & marketing down 37% to $101M.

12-03-2026

Blue Ridge Bankshares, Inc. reported net income of $10.7M for the year ended December 31, 2025, marking a turnaround from a $15.4M net loss in 2024, primarily due to a 28.0% decline in noninterest expenses to $81.9M and provision recoveries of $4.0M. However, net interest income was nearly flat at $78.9M (up 0.3% YoY), interest income fell 14.0% to $137.8M amid an 11.7% drop in loans held for investment to $1.87B and a 12.3% contraction in deposits to $1.91B, while total assets decreased 11.1% to $2.43B. Noninterest income also declined 5.4% to $12.8M, reflecting weakness in residential mortgage banking and other fee income.

• ·Nonperforming assets stable at $25.4M (1.05% of total assets) as of Dec 31, 2025 vs $25.7M (0.94%) as of Dec 31, 2024.
• ·Allowance for credit losses to loans held for investment improved slightly to 1.04% as of Dec 31, 2025 from 1.09%.
• ·Provision for credit losses was a recovery of $4.0M in 2025 vs $5.1M recovery in 2024.
• ·Net interest margin expanded to 3.17% in 2025 from 2.77% in 2024.
• ·Diluted EPS from continuing operations $0.11 in 2025 vs $(0.31) in 2024; dividends declared $0.250 per share in 2025 vs $0.

12-03-2026

Calavo Growers Inc reported Q1 FY2026 net sales of $122.2M, down 21% YoY from $154.4M, driven by declines in fresh avocados (-23%) and tomatoes (-47%), though prepared guacamole sales rose 20% YoY to $17.5M. Gross profit dipped 3% to $15.2M, but SG&A expenses surged 59% to $16.4M, resulting in an operating loss of $1.4M versus $5.0M profit prior year; net income fell 82% to $0.8M. Cash and equivalents declined to $47.7M from $61.2M QoQ amid $8.7M operating cash use.

• ·Foreign currency gain of $2.6M in Q1 FY2026 vs loss of $1.0M prior year
• ·Operating cash flow used $8.7M in Q1 FY2026 vs $4.4M prior year
• ·Dividend declared $0.20 per share, total $3.6M
• ·Mexico tax liability steady at $11M
• ·Gain on sale of Temecula packinghouse $55K

12-03-2026

Health Catalyst, Inc. reported total revenue of $311.1M for the year ended December 31, 2025, up 1.5% YoY from $306.6M in 2024, with Technology segment revenue growing 6.9% to $208.3M while Professional Services revenue declined 8.0% to $102.9M. Adjusted EBITDA improved significantly 58.6% to $41.4M, and gross margin expanded to 39% from 37%, but net loss widened dramatically to $178.0M from $69.5M, driven by a $110.2M impairment of goodwill and intangible assets. Adjusted gross margin rose to 51% from 49%.

• ·Operating expenses totaled $312.5M in 2025, down from $210.6M in 2024 but elevated due to $110.2M impairment.
• ·Stock-based compensation expense decreased to $27.0M in 2025 from $40.1M in 2024.
• ·Sales and marketing expenses $52.5M in 2025, down from $54.4M in 2024; R&D $49.8M down from $57.9M.

12-03-2026

OppFi Inc. reported total revenue of $597M for FY2025, up 13.5% YoY from $526M, with net revenue rising 18.6% to $381M and income from operations surging 76.3% to $167M, driving net income attributable to OppFi to $26M, up 262.8% YoY. Adjusted net income grew 69.1% to $140M with adjusted EPS of $1.59. However, the change in fair value of finance receivables worsened 5.6% to a $216M loss, salaries and employee benefits remained essentially flat at $61M (+0.4%), and total debt was nearly flat at $321M (+0.8%).

• ·Net charge-offs improved to 37.0% of total revenue (from 39.1%) and 49.4% of average receivables (from 51.4%) in FY2025.
• ·Unrestricted cash was $49M at Dec 31, 2025 (down from $61M in 2024); undrawn debt $204M.
• ·Net cash from operations up to $401M in FY2025 from $324M in 2024.
• ·Equity method investment slightly down 0.6% to $19M at Dec 31, 2025.
• ·Other adjustments net $12.2M in FY2025, including $10M stock compensation and $1.2M legal matters.

12-03-2026

Champions Oncology, Inc. reported oncology revenue of $45.6M for the nine months ended January 31, 2026, up 2.2% YoY from $44.6M, but incurred an operating loss of $0.6M versus a $6.6M profit prior year due to sharply higher costs across cost of revenue (+14%), R&D (+43%), and other expenses. For the three months ended January 31, 2026, revenue fell 2.8% YoY to $16.6M, swinging to a $0.3M net loss from a $4.5M profit. Total assets declined to $28.4M from $32.3M at April 30, 2025, with cash at $7.1M (down from $9.8M), though stockholders' equity rose to $4.4M from $3.8M.

• ·Cost of oncology revenue for nine months increased 14.0% YoY to $24.1M from $21.1M.
• ·Research and development expenses for nine months rose 43.4% YoY to $7.0M from $4.9M.
• ·Net cash used in operating activities for nine months was $2.5M, versus $0.5M provided prior year.
• ·Accounts receivable, net increased to $12.1M as of Jan 31, 2026 from $11.2M at Apr 30, 2025.

12-03-2026

Oncology Institute, Inc. reported total operating revenue of $502.7M for the year ended December 31, 2025, up 27.8% YoY from $393.4M, driven by strong 49.6% growth in specialty pharmacy ($269.2M) and 11.8% increase in patient services ($229.0M), though clinical trials revenue declined 47.0% to $4.6M. Adjusted EBITDA improved significantly by 65.2% to -$12.4M from -$35.7M, and net loss narrowed 6.3% to -$60.6M; however, total operating expenses rose 18.8% to $538.8M, loss from operations was still -7.2% of revenue, and cash equivalents fell 32.4% to $33.6M.

• ·Affiliated and Network Clinics increased to 146 from 86 (+69.8% YoY).
• ·Markets expanded to 17 from 16 (+6.3% YoY).
• ·Lives under value-based contracts grew to 2.0M from 1.9M (+5.3% YoY).
• ·Selling, general and administrative expense declined 2.1% YoY to $105.6M.
• ·Net cash used in operating activities improved 7.4% to $24.6M used.

12-03-2026

Volato Group, Inc. reported revenue more than doubling YoY to $78.6M for the year ended December 31, 2025, from $39.1M in 2024, driven by aircraft sales (+102% to $77.1M) and subscriptions (+60% to $1.5M), achieving net income of $5.2M versus a $40.6M loss prior year and positive operating income of $4.0M versus an $8.6M loss. However, total assets shrank to $12.0M from $46.3M, total costs and expenses rose 56% to $74.6M, and net cash used in investing activities increased significantly to $8.1M.

• ·Weighted average basic shares outstanding increased to 4.4M in 2025 from 1.7M in 2024.
• ·Basic and diluted EPS from continuing operations improved to $0.19 from -$12.73.
• ·Shareholders' deficit improved to -$1.8M from -$16.3M, with additional paid-in capital at $98.9M.

12-03-2026

Legacy Housing Corp (LEGH) operates an expansive distribution network across 15 states with 14 company-owned retail locations and over 80 independent retail locations as of December 31, 2025, alongside financing for over 80 independent retailers and more than 4,300 retail customers. The company owns over 1,000 acres of land in Texas and focuses on vertically integrated solutions for manufactured home communities. Product sales concentration in Texas slightly declined to 52% in 2025 from 54% in 2024, Georgia fell to 8% from 11%, while Oklahoma remained flat at 6%, and states like Florida, Tennessee, and Louisiana saw increases.

• ·First company-owned retail location opened in June 2016.
• ·Arkansas product sales entered at 2% in 2025 (0% in 2024).

12-03-2026

loanDepot, Inc. reported total net revenues of $1.19B for 2025, up 12.2% YoY from $1.06B, driven by a 15.6% increase in gain on origination and sale of loans to $742.4M and origination income up 60.1% to $131.7M. However, the company recorded a net loss attributable to loanDepot of $62.6M, improved 36.3% from $98.3M prior year, with purchase loan originations declining 6.2% to $15.2B while refinance originations surged 36% to $11.3B; servicing fee income fell 9.2% to $437.2M and total expenses edged up 0.6%. Total loan originations rose 8.1% to $26.5B, but the servicing portfolio UPB grew modestly 2.7% to $119.1B amid rising 60+ day delinquencies to 1.60% from 1.57%.

• ·Licensed loan officers declined to 1,599 from 1,728 YoY.
• ·Headcount reduced to 4,506 from 4,675 YoY.
• ·Total assets grew 8.1% to $6.86B, but equity fell 23.8% to $386M.
• ·Adjusted total revenue $1.21B in 2025 vs $1.10B in 2024.
• ·Adjusted net loss $65.6M in 2025 vs $94.8M in 2024.